

CERTIFICATE OF ANALYSIS

Product Name	GV1001 peptide, Cat.#: 319567 (TFA removed)
Lot No.	MTFB20841-260514
Sequence	EARPALLTSRLRFIPK (HCl Salt)
Dissolution condition	100%H ₂ O
Modification	HCL salt
Molecular Weight (MW)	1868.33
Storage	-20°C

Test Items	Specifications	Results
MW by MS	1868.55	Conforms
Purity by HPLC	>95%	97.790%
Endotoxin Content	N/A	N/A
TFA solubility	N/A	N/A
Moisture content	N/A	N/A
Peptide content	N/A	N/A
Appearance	White to off-white lyophilized powder	Conforms
Quantity	200mg	5.0mg*40

NovoPro Bioscience Inc. (hereafter NovoPro) warrants material of said quality at the time of sale. It is the sole responsibility of the customers to determine the adequacy of all materials for any intended or specific purpose or use. NovoPro's sole obligation is to replace the material up to the extent of the purchase price. This warranty applies only to products in original packaging and does not apply to a product which has been tampered with or altered in any way in or which has been misused or damaged by accident or negligence. All claims must be received writing (by fax or email) within 30 days from date when product arrive at the destination city and failure to do so shall constitute a waiver by customers for any and all such claims.

Certified by:



May/18/2026

Quality Assurance Department




Sample Information

Order ID :MTFB20841
 Name :GV1001 peptide, Cat.#: 319567 (TFA removed)
 Sequence :EARPALLTSRLRFIPK (HCl Salt)
 Lot. No :MTFB20841-260514
 Pump A :0.1%Trifluoroacetic in 100% water
 Pump B :0.1%Trifluoroacetic in 100% acetonitrile
 Total Flow :1ml/min
 Wavelength :214nm
 Analytical column type :Kromasil 100-5-C18 (4.6*250mm*5 µm)
 Dissolution method :100%H₂O
 Inj. Volume : 15ul

Time	Module	Action	Value
0.01	Pumps	B.Conc	20
30.00	Pumps	B.Conc	50
33.00	Pumps	B.Conc	100
38.00	Pumps	B.Conc	100
40.00	Pumps	B.Conc	20
50.00	Controller	Stop	

Chromatogram




Peak Table

Detector A 214nm

Peak#	Ret. Time	Area	Height	Area%
1	8.493	969	154	0.021
2	12.100	16074	567	0.345
3	12.794	4561608	562121	97.790
4	13.971	84306	8765	1.807
5	18.040	1722	224	0.037
Total		4664680	571831	100.000

MS Spectrum



Sample Information

Dissolution method	:15%ACN+85%H2O	Interface	:ESI	Prerod Bias	:+4.5kv
Date Acquired	:2026/05/15 11:02:42	Nebulizing Gas Flow	:1.50L/min	Detector	:-0.2kv
Injection Volume	:0.2ul	CDL Temp	:250°C	T.Flow	:0.2ml/min
Block Temp	:200	CDL Volt	:0v	B.conc	:50%H2O/50%MEOH
Order ID	:MTFB20841				
Name	:GV1001 peptide, Cat.#: 319567 (TFA removed)				
Sequence	:EARPALLTSRLRFIPK(HCl Salt)				
Lot.No	:MTFB20841-260514				
Theoretical	:1868.33				
Observed	:1868.55				

Instructions for dissolving GV1001 peptide

The GV1001 peptide is soluble in pure water, 1 x PBS, or Bacteriostatic (BAC) water.

The suggested concentration is 5.0 mg/ml.

The steps are as below:

1. Adding 1.0 ml ultrapure water to the 2.0 ml tube of GV1001;
2. Wait about 1 minute at room temperature until the solution is clear, which indicates the peptide is fully dissolved;
3. Use a sterile 0.22 μ m membrane filter for a particle-free and bacteria-free GV1001 solution.
For example, Catalog# SLGPR33RB, Millipore Millex-GP Syringe Filter Unit, 0.22 μ m, polyethersulfone, 33 mm, gamma sterilized.

References of GV1001:

1. Kyte JA. Cancer vaccination with telomerase peptide GV1001. Expert Opin Investig Drugs. 2009 May;18(5):687-94.
<https://doi.org/10.1517/13543780902897631>
2. Park HH, et al. Novel vaccine peptide GV1001 effectively blocks β -amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase. Neurobiol Aging. 2014 Jun;35(6):1255-74.
<https://doi.org/10.1016/j.neurobiolaging.2013.12.015>
3. Koh SH, et al. Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. Alzheimers Res Ther. 2021 Mar 26;13(1):66.
<https://doi.org/10.1186/s13195-021-00803-w>